Sidoti & Co. Upgrades Staar Surgical to Buy
Sidoti & Co. analyst James Sidoti upgrades Staar Surgical (NASDAQ:STAA) from Neutral to Buy.
Wells Fargo Upgrades NOV to Equal-Weight, Raises Price Target to $25
Wells Fargo analyst Roger Read upgrades NOV (NYSE:NOV) from Underweight to Equal-Weight and raises the price target from $16 to $25.
Raymond James Upgrades Profound Medical to Strong Buy
Raymond James analyst Rahul Sarugaser upgrades Profound Medical (NASDAQ:PROF) from Outperform to Strong Buy.
B of A Securities Upgrades Cardinal Health to Neutral, Raises Price Target to $80
B of A Securities analyst Michael Cherny upgrades Cardinal Health (NYSE:CAH) from Underperform to Neutral and raises the price target from $64 to $80.
JP Morgan Upgrades GoodRx Holdings to Neutral, Lowers Price Target to $8
JP Morgan analyst Doug Anmuth upgrades GoodRx Holdings (NASDAQ:GDRX) from Underweight to Neutral and lowers the price target from $10 to $8.
Raymond James Upgrades Kemper to Outperform, Announces $60 Price Target
Raymond James analyst C. Gregory Peters upgrades Kemper (NYSE:KMPR) from Market Perform to Outperform and announces $60 price target.
Citigroup Upgrades Penumbra to Buy, Lowers Price Target to $212
Citigroup analyst Joanne Wuensch upgrades Penumbra (NYSE:PEN) from Neutral to Buy and lowers the price target from $217 to $212.
Piper Sandler Upgrades Insulet to Overweight, Raises Price Target to $340
Piper Sandler analyst Matt O'Brien upgrades Insulet (NASDAQ:PODD) from Neutral to Overweight and raises the price target from $235 to $340.
Canaccord Genuity Upgrades Cineplex to Buy, Lowers Price Target to C$13
Canaccord Genuity analyst Aravinda Galappatthige upgrades Cineplex (TSX:CGX) from Speculative Buy to Buy and lowers the price target from C$16 to C$13.
